Nektar Therapeutics NKTR Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Nektar Therapeutics (NKTR) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $1.04M in Q1 2026.
- How has Nektar Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Nektar Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 2311.6% year-over-year, from $43K to $1.04M.
- What is the long-term trend for Nektar Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 2 years (2020 to 2022), Nektar Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a 200.0% compound annual growth rate (CAGR), from $200K to $1.8M.